New York, NY -- (SBWIRE) -- 01/02/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Quiksilver, Inc (NYSE:ZQK), Achillion Pharmaceuticals, Inc (NASDAQ:ACHN), Hemispherx BioPharma, Inc (NYSEMKT:HEB), Precision Drilling Corp (USA) (NYSE:PDS)
Quiksilver, Inc (NYSE:ZQK) showed a volume of 1.42 million shares by the end of last trade whereas the average volume of the stock remained 1.58 million shares. The stock opened the session at $8.74 but then moved to $8.77. At that price, the stock showed a positive performance of 0.46%. Quiksilver, Inc. is a diversified company that designs, develops and distributes branded apparel, footwear, accessories and related products, catering to the casual, youth lifestyle associated with the sports of surfing, skateboarding and snowboarding. It markets products across three core brands: Quiksilver, Roxy and DC, as well as several smaller brands.
Will ZQK Continue To Move Higher? Find Out Here
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) opened the session at $3.31 and closed the session at $3.32. The stock showed a positive performance of 1.81% in previous trading session. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections.
For How Long ACHN will fight for Profitability? Read This Trend Analysis report
Hemispherx BioPharma, Inc (NYSEMKT:HEB) opened the session at $0.25 and closed the session at $0.265. The stock showed a positive performance of 5.08% in previous trading session. Traded with volume of 1.40 million shares in the prior session and the average volume of the stock remained 1.76 million shares. The beta of the stock remained 1.76. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development.
Why Should Investors Buy HEB After The Recent Gain? Just Go Here and Find Out
Precision Drilling Corp (USA) (NYSE:PDS) the stock advanced 0.75% and finished the session at $9.37. Traded with volume of 1.37 million shares in the prior session and the average volume of the stock remained 1.42 million shares. The beta of the stock remained 2.71. Precision Drilling Corporation (Precision) is a provider of contract drilling and completion and production services primarily to oil and natural gas exploration and production companies in Canada and the United States. The Company operates in two segments: Contract Drilling Services, and Completion and Production Services. In Canada, the Contract Drilling Services segment includes land drilling services, directional drilling services,
Will PDS Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)